Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532687 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01532687 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 54 participants.
The verdict
NCT01532687, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is more effective with or without pazopanib hydrochloride in treating patients with soft tissue sarcoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Gemcitabine
- DRUG Gemcitabine Hydrochloride
- DRUG Pazopanib
- DRUG Pazopanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-03-13 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532687
The ClinicalTrials.gov registry entry for NCT01532687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01532687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532687 about?
NCT01532687 is a clinical study titled "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma". This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, e...
What is the current status of trial NCT01532687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2012-03-13. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT01532687?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Gemcitabine (DRUG), Gemcitabine Hydrochloride (DRUG), Pazopanib (DRUG), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01532687?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.